Norcantharidin enhances ABT-263-mediated anticancer activity in neuroblastoma cells by upregulation of Noxa

Wang,Xiaohui; Gu,Zhimin; Li,Gongquan; Zhang,Shufeng; Cao,Zhenjie; Yang,Zhanfeng; Liu,Guangzhi

doi:10.3892/or.2014.3228

Norcantharidin enhances ABT-263-mediated anticancer activity in neuroblastoma cells by upregulation of Noxa

Authors:
- Xiaohui Wang
- Zhimin Gu
- Gongquan Li
- Shufeng Zhang
- Zhenjie Cao
- Zhanfeng Yang
- Guangzhi Liu
View Affiliations

Affiliations: Department of Pediatric Surgery, People's Hospital of Zhengzhou University, Zhengzhou, Henan 450003, P.R. China, Department of Ophthalmology, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450003, P.R. China, Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450003, P.R. China, Department of Pediatric Surgery, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450003, P.R. China, Department of Hepatobiliary Surgery, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450003, P.R. China, Department of Obstetrics and Gynecology, People's Hospital of Zhengzhou University, Zhengzhou, Henan 450003, P.R. China
Published online on: May 30, 2014 https://doi.org/10.3892/or.2014.3228
Pages: 716-722

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Neuroblastoma is an aggressive childhood disease. Even with intensive conventional treatments, the long term survival rate for children with neuroblastoma remains less than 40%, highlighting the importance of finding new therapies. Bcl-2 family proteins play crucial roles in survival, proliferation and chemotherapeutic resistance of neuroblastoma cells. Therefore, targeting Bcl-2 with small molecule inhibitor ABT-263 could be a novel strategy for treatment of neuroblastoma. However, previous studies indicated that most neuroblastoma cell lines are resistant to ABT-263-mediated apoptosis. Thus, it is crucial to discover approaches that could overcome ABT-263 resistance. In this study, we examined the anticancer activity of ABT-263 in combination with norcantharidin (NCTD), a small-molecule anticancer drug derived from a traditional Chinese medicine, in human malignant neuroblastoma cells. We found that NCTD substantially enhanced ABT-263-mediated apoptosis induction, cell viability inhibition, and clonal formation inhibition in neuroblastoma SH-SY5Y and CHLA-119 cell lines. Moreover, the combination anticancer activity was accompanied by upregulation of Noxa, and was associated with characteristics of mitochondrial apoptosis signaling, such as cytosolic release of cytochrome c, activation of caspase-9,-3, and cleavage of PARP. Notably, we observed that knockdown of Noxa significantly attenuated cell death induction by cotreatment with ABT-263 and NCTD, indicating Noxa essentially contributes to the combination anticancer effect. Collectively, our study demonstrated that NCTD could overcome ABT-263-resistance in neuroblastoma cells, and suggested that combinational treatment of ABT-263 with NCTD might be a novel therapeutic option for children with neuroblastoma.

View Figures

View References

1	Meadows A, Baum E, Fossati-Bellani F, et al: Second malignant neoplasms in children: an update from the late effects study group. J Clin Oncol. 3:532–538. 1985.PubMed/NCBI
2	Welch C, Chen Y and Stallings R: MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene. 26:5017–5022. 2007. View Article : Google Scholar : PubMed/NCBI
3	George R, Sanda T, Hanna M, et al: Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 455:975–978. 2008. View Article : Google Scholar : PubMed/NCBI
4	Goldsmith K, Lestini B, Gross M, et al: BH3 response profiles from neuroblastoma mitochondria predict activity of small molecule Bcl-2 family antagonists. Cell Death Differ. 17:872–882. 2010. View Article : Google Scholar : PubMed/NCBI
5	Kroemer G: The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nature Med. 3:614–620. 1997. View Article : Google Scholar : PubMed/NCBI
6	Fang H, Harned T, Kalous O, Maldonado V, DeClerck Y and Reynolds C: Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma. Clin Cancer Res. 17:7093–7104. 2011. View Article : Google Scholar : PubMed/NCBI
7	Castle V, Heidelberger K, Bromberg J, Ou X, Dole M and Nuñez G: Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification. Am J Pathol. 143:1543–1550. 1993.PubMed/NCBI
8	Dole M, Nuñez G, Merchant A, Maybaum J, Rode C, Bloch C and Castle V: Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res. 54:3253–3259. 1994.PubMed/NCBI
9	Hanada M, Krajewski S, Tanaka S, et al: Regulation of Bcl-2 oncoprotein levels with differentiation of human neuroblastoma cells. Cancer Res. 53:4978–4986. 1993.PubMed/NCBI
10	Tse C, Shoemaker A, Adickes J, et al: ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68:3421–3428. 2008. View Article : Google Scholar : PubMed/NCBI
11	Oltersdorf T, Elmore S, Shoemaker A, et al: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 435:677–681. 2005. View Article : Google Scholar : PubMed/NCBI
12	Gandhi L, Camidge D, Ribeiro de Oliveira M, et al: Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol. 29:909–916. 2011. View Article : Google Scholar : PubMed/NCBI
13	Rudin C, Hann C, Garon E, et al: Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res. 18:3163–3169. 2012. View Article : Google Scholar : PubMed/NCBI
14	Konopleva M, Contractor R, Tsao T, et al: Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 10:375–388. 2006. View Article : Google Scholar : PubMed/NCBI
15	Billard C: BH3 mimetics: status of the field and new developments. Mol Cancer Ther. 12:1691–1700. 2013. View Article : Google Scholar : PubMed/NCBI
16	Goldsmith K, Gross M, Peirce S, et al: Mitochondrial Bcl-2 family dynamics define therapy response and resistance in neuroblastoma. Cancer Res. 72:2565–2577. 2012. View Article : Google Scholar : PubMed/NCBI
17	Klymenko T, Brandenburg M, Morrow C, Dive C and Makin G: The novel Bcl-2 inhibitor ABT-737 is more effective in hypoxia and is able to reverse hypoxia-induced drug resistance in neuroblastoma cells. Mol Cancer Ther. 10:2373–2383. 2011. View Article : Google Scholar : PubMed/NCBI
18	Wang G: Medical uses of mylabris in ancient China and recent studies. J Ethnopharmacol. 26:147–162. 1989. View Article : Google Scholar : PubMed/NCBI
19	Yang E, Tang W, Zhang K, Cheng L and Mack PO: Norcantharidin inhibits growth of human HepG2 cell-transplanted tumor in nude mice and prolongs host survival. Cancer Lett. 117:93–98. 1997. View Article : Google Scholar : PubMed/NCBI
20	Kok SH, Cheng SJ, Hong CY, et al: Norcantharidin-induced apoptosis in oral cancer cells is associated with an increase of proapoptotic to antiapoptotic protein ratio. Cancer Lett. 217:43–52. 2005. View Article : Google Scholar : PubMed/NCBI
21	Zhang S, Li G, Ma X, et al: Norcantharidin enhances ABT-737-induced apoptosis in hepatocellular carcinoma cells by transcriptional repression of Mcl-1. Cell Signal. 24:1803–1809. 2012. View Article : Google Scholar : PubMed/NCBI
22	Huang Y, Liu Q, Liu K, Yagasaki K and Zhang G: Suppression of growth of highly-metastatic human breast cancer cells by norcantharidin and its mechanisms of action. Cytotechnology. 59:201–208. 2009. View Article : Google Scholar
23	Yang J, Liu X, Bhalla K, et al: Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science. 275:1129–1132. 1997. View Article : Google Scholar : PubMed/NCBI
24	Green DR and Kroemer G: The pathophysiology of mitochondrial cell death. Science. 305:626–629. 2004. View Article : Google Scholar : PubMed/NCBI
25	Mazumder S, Choudhary G, Al-Harbi S and Almasan A: Mcl-1 phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells. Cancer Res. 72:3069–3079. 2012. View Article : Google Scholar : PubMed/NCBI
26	Okumura K, Huang S and Sinicrope F: Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737. Clin Cancer Res. 14:8132–8142. 2008. View Article : Google Scholar : PubMed/NCBI
27	Simonin K, N’Diaye M, Lheureux S, et al: Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis. Apoptosis. 18:492–508. 2013. View Article : Google Scholar : PubMed/NCBI
28	Zinn R, Gardner E, Dobromilskaya I, et al: Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer. Mol Cancer. 12:Mar 2–2013. View Article : Google Scholar
29	Yang PY, Chen MF, Kao YH, et al: Norcantharidin induces apoptosis of breast cancer cells: involvement of activities of mitogen activated protein kinases and signal transducers and activators of transcription. Toxicol In Vitro. 25:699–707. 2011. View Article : Google Scholar : PubMed/NCBI